Moderna has launched the first trial of the HIV mRNA vaccine, the company . Thursday, it released the first shot of a shot made by a for volunteers at the George Washington University School of Medicine and Health Science.
Like the COVID-19 vaccine, this new treatment uses messenger RNA to “trick” the human body into making proteins that can trigger the immune system. Moderna hopes that the shot will trigger a group of white blood cells known as B-cells, which can be unmodified antibodies. Those proteins are “considered to be the target of HIV vaccination, and this is the first step in the process,” according to the company.
As part of the test, Moderna wants to test the first vaccine as well as additional shots. The Phase 1 trial will affect 56 healthy people, who are HIV-negative. The company is providing 48 of these people with the mRNA vaccine. Thirty-two of the team will also receive an inspiring shot. For the last eight that were tested in the first test, the company only offers an inspiring shot. Moderna says she has been monitoring the whole team for six months to check for vaccine safety. It is also designed to test the immune response that the vaccine triggers at the cellular level to see if it is effective.
Messenger RNA technology can lead to the treatment of many deadly diseases, including , but the success of HIV can be very impressive. According to statistics from , an estimated 1.2 million Americans are infected with the virus, which can lead to the deadly AIDS epidemic. Although the HIV status of HIV patients has been improving since the 90’s due to the development of new drugs and drugs, no HIV vaccine has passed the first clinical trials.
All sales supported by Engadget are selected by our writing team, independent of our parent company. Some of our articles include links to links. When you purchase something through one of these links, we may be able to find a partner.
Source link
